




TRIPLE NEGATIVE BREAST CANCER (TNBC) GLOBAL CLINICAL TRIAL LANDSCAPE (2024)

#DYK
Did you know?



Marketed drugs such as **Immune checkpoint inhibitors** (e.g., Keytruda) and antibody-drug conjugates (e.g., Trodelvy) are vital in targeting TNBC pathways



Phase III trials focus on innovative **ADCs** (e.g., datopotamab deruxtecan) and **immune therapies** (e.g., adagloxad simolenin), driving progress in TNBC treatment

TNBC is a **highly aggressive** and heterogeneous subtype,

In the Asia-Pacific region, **China** reported an estimated higher incidence of TNBC cases

In Europe, **Germany** reported an estimated higher incidence of TNBC

The **United States** had the highest estimated number of TNBC cases in North America

In ROW, **Brazil** reported the highest incidence of TNBC



comprising **10-15%** of **global breast cancer cases**

Triple Negative Breast Cancer TRIAL CONTRIBUTIONS

The **Asia-Pacific** region shows **faster recruitment rates** than the United States

